| Study | Reason for exclusion |
|---|---|
| Adeboyeku 2001 | Study of safety and tolerability of an eradication protocol for P. aeruginosa. |
| Amelina 2000 | Study of effects of home IVs for exacerbations of CF bronchiectasis on lung function and QoL in CF. |
| Carswell 1987 | Study of eradication protocols for P. aeruginosa colonisation. |
| Chua 1990 | Assessment of bronchial responsiveness to nebulised antibiotics, pathogen not specified. |
| Conway 1996 | Assessment of different combinations of IV antibiotics in the treatment of exacerbations of CF bronchiectasis, pathogen not specified. |
| Cooper 1985 | Assessment of different combinations of IV antibiotics in the treatment of exacerbations of CF bronchiectasis, pathogen not specified. |
| Davis 1987 | Study of the pharmacokinetics of ciprofloxacin in people with CF, pathogen not specified. |
| Degg 1996 | Evaluation of the ototoxic effects of gentamicin on people with CF, pathogen not specified. |
| Dodd 1997 | Study of the correlation between tonicity and adverse effects of nebulised colistin in CF, pathogen not specified. |
| Dodd 1998 | Discussion of the discrepancy between patient‐reported and objectively assessed non‐compliance in clinical studies, neither drug or pathogen specified. |
| Frederiksen 2006 | No participants infected with BCC in study. |
| Geller 2004 | Pharmacokinetics, safety and efficacy of nebulised tobramycin in CF, pathogen not specified. |
| Goldfarb 1986 | Pharmacokinetics of single dose oral ciprofloxacin in people with CF, pathogen not specified. |
| Griffith 2008 | Pharmacokinetics of single dose nebulised levofloxacin in people with CF, pathogen not specified. |
| Gulliver 2003 | Study of tolerance of nebulised tobramycin in people with CF, pathogen not specified. |
| Heininger 1993 | Comparison of different dose regimens of aminoglycosides in exacerbations of CF bronchiectasis, pathogen not specified. |
| Hjelte 1988 | Study of QoL for people with CF with home versus inpatient IV antibiotics for exacerbations. |
| Hodges 2014 | Pharmacokinetic study. |
| Huang 1979 | Study of a novel scoring system for assessing the efficacy of IV antibiotic regimens in exacerbations of CF bronchiectasis. |
| Huang 1982 | Strategy for eradication of P. aeruginosa. |
| Huls 2000 | Study of the effects of lung function on serum concentrations of antibiotics, pathogen not specified. |
| Kapranov 1995 | Strategy for eradication of P. aeruginosa. |
| Keller 2010 | Investigation of the efficacy of delivery of a novel therapeutic preparation of nebulised tobramycin, pathogen not specified. |
| Khorasani 2009 | Study examined the role of zinc supplementation in reducing frequency of pulmonary exacerbations in CF. |
| Knight 1979 | Eradication strategy for P. aeruginosa. |
| Kruger 2001 | Report of ototoxicity of IV tobramycin in people with CF, pathogen not specified. |
| Labiris 2004 | Investigation of whether inhalation of preservatives from IV tobramycin preparations causes airway inflammation in CF, pathogen not specified. |
| Ledson 2002 | Cross‐over study of B. cepacia therapy, study design not eligible. |
| Loening‐Bauke 1979 | Comparison of long‐term options for eradication of P. aeruginosa. |
| Nathanson 1985 | Study of efficacy of nebulised gentamicin in CF, pathogen not specified. |
| NCT00298922 | Due to delays in starting related to getting placebo, the investigators were not able to enrol the intended sample size. The study was negative but was underpowered. Initial attempts to get it published were unsuccessful and hence the investigators did not persist. |
| Pai 2006 | Pharmacokinetics of levofloxacin in adults with CF, pathogen not specified. |
| Postnikov 2000 | Study of tolerance and efficacy of pefloxacin as a prophylaxis and treatment of severe infections in children with CF and aplastic anaemia, pathogen not specified. |
| Postnikov 2001 | Study of safety of fluoroquinolones in children, pathogen not specified. |
| Postnikov 2001a | Comparison of growth rates of children with CF either treated or not treated with ciprofloxacin, pathogen not specified. |
| Prayle 2016 | Pharmacokinetic study. |
| Ramstrom 2000 | Study of the effects of altered methods of preparation of home IV antibiotic therapies in CF. |
| Roberts 1993 | Study of interactions of tobramycin and ticarcillin in CF, pathogen not specified. |
| Romano 1991 | Non‐blinded study of ofloxacin for people with CF requiring long‐term antibiotics with 'sensitive' sputum culture (pathogens unknown). |
| Romano 1992 | Non‐blinded study of ofloxacin for people with CF requiring long‐term antibiotics with 'sensitive' sputum culture (pathogens unknown). |
| Rosenfeld 2006 | Study of accumulation of nebulised tobramycin in respiratory secretions, pathogen not specified. |
| Rye 2015 | Cross‐over study of B. cepacia therapy, study design not eligible. |
| Salh 1992 | Study of antibiotic regimens for treatment of CF bronchiectasis exacerbations, pathogen not specified. |
| Sharma 2016 | Study examined the role of zinc supplementation in reducing frequency of pulmonary exacerbations in CF. |
| Singh 2013 | Study focused on reducing early pulmonary infections in CF, not including BCC. |
| Smith 1997 | Study of the uses of salivary ciprofloxacin concentrations in people with CF, pathogen not specified. |
| Stutman 1987 | Comparison of different dose regimens of oral ciprofloxacin in chronically infected people with CF, pathogen not specified. |
| Tullis 2014 | RCT of treatment for people with chronic B. cepacia infection. |
| Uluer 2013 | Open‐label design with no control group; treatment offered to all people with CF with Burkholderia dolosa. |
| Vitti 1975 | Study of effectiveness of pancreatic enzyme supplements on absorption of oral antibiotics in CF. |
| Wood 1996 | Study of minimisation of aminoglycoside toxicity in CF. |
B. cepacia: Burkholderia cepacia CF: cystic fibrosis IV: intravenous P aeruginosa: Pseudomonas aeruginosa QoL: quality of life RCT: randomised controlled trial